Positive Phase 2 data with strong biomarker reductions and GC-sparing effect increases probability of Phase 3 success in classic CAH. Monitor enrollment updates and any regulatory feedback on Phase 3 design. ADCS data is early but adds optionality. Watch for potential partnership or financing given advancing pipeline costs.
Price Chart
Executive Summary
Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12 while enabling 88% of patients to reach physiologic glucocorticoid doses. New Phase 1b/2a data in ACTH-dependent Cushing's syndrome also showed rapid cortisol normalization. Management is advancing atumelnant to Phase 3 CALM-CAH trial which is already enrolling.
Key Facts
- Mean A4 reduction of 67% from baseline at week 12 in Cohort 4 (80 mg morning dosing with GC reduction)
- 88% of Cohort 4 participants (7/8) achieved physiologic daily GC dose at week 12
- Atumelnant 40-120 mg once daily produced -58% to -80% A4 reductions across all cohorts 1-3 without GC reduction
- Phase 1b/2a ADCS data showed rapid lowering of early morning cortisol and UFC normalization in 3/6 participants at 40 mg dose
- Atumelnant advancing to Phase 3 CALM-CAH trial which is already enrolling patients
- No treatment-related severe or serious adverse events reported across any dose level
Financial Impact
No financial figures provided; Phase 2 data readout supports atumelnant's advancement to Phase 3, de-risking the program for a $3.6B market cap biotech with one approved product (PALSONIFY) and pipeline value tied to atumelnant
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 biomarker results on primary endpoints
- Adrenal insufficiency AEs in ADCS trial require careful management and could limit commercial uptake
- Competing therapies for CAH (e.g., Eton Pharmaceuticals' chronocort) could limit market share
- Crinetics has $3.6B market cap with only one approved product — pipeline success is critical
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311470 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access